Almost 300 million people worldwide are living with chronic hepatitis B, often leading to life-threatening complications such as cirrhosis or hepatocellular carcinoma.  

WHO estimates that 12-25% of patients with chronic hepatitis B are eligible for drug therapy, which must be  continued lifelong. The treatment aims to stop viral replication and to slow down the progression of the disease.  

Measuring the viral load by quantification of HBV DNA allows treatment assessment, monitoring of disease progression and viral response to antiviral treatment.

Rapid and accurate quantification of the hepatitis B viral load 

GENERIC HBV CHARGE VIRALE version 2.0 is a highly sensitive and accurate test for quantification of HBV DNA from plasma EDTA samples.  

The automated extraction with the GenoXtract®, in combination with GXT NA Extraction kits, provides high quality nucleic acid extraction for optimal PCR performance.

GENERIC HBV CHARGE VIRALE version 2.0 can easily be implemented in the routine analysis workflow using  existing laboratory equipment, as the commonly available thermocyclers are validated with the assay.

Particularly,  the FluoroCycler® XT provides fully automated analysis with FluoroSoftware® XT-IVD generating results at a glance, in an easy-to-use, easy-to-interpret test report.